238 related articles for article (PubMed ID: 19354077)
1. High-dose sublingual immunotherapy in children at 8-year follow-up.
Leonardi S; Spicuzza L; La Rosa M
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):259-60. PubMed ID: 19354077
[No Abstract] [Full Text] [Related]
2. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
3. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
4. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy: allergen specific or placebo effect?
Kette F; Smith W
J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
[No Abstract] [Full Text] [Related]
6. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
7. Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.
Creticos PS; Pfaar O
Immunotherapy; 2018 Jun; 10(7):605-616. PubMed ID: 29634392
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
9. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy.
Corrigan C
J Allergy Clin Immunol; 2007 Feb; 119(2):515; author reply 515-7. PubMed ID: 17187850
[No Abstract] [Full Text] [Related]
12. Rush immunotherapy with sublingual administration of grass allergen extract.
Feliziani V; Marfisi RM; Parmiani S
Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
[TBL] [Abstract][Full Text] [Related]
13. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy.
Ventura MT; Carretta A; Tummolo RA; Buquicchio R; Arsieni A; Murgia N
Int J Immunopathol Pharmacol; 2009; 22(2):403-13. PubMed ID: 19505393
[TBL] [Abstract][Full Text] [Related]
14. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of sublingual immunotherapy in children.
Bufe A
Drugs Today (Barc); 2008 Dec; 44 Suppl B():61-3. PubMed ID: 19221622
[No Abstract] [Full Text] [Related]
16. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
17. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis.
Agostinis F; Forti S; Di Berardino F
Allergy; 2010 Mar; 65(3):410-1. PubMed ID: 19804450
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.
Wahn U; Tabar A; Kuna P; Halken S; Montagut A; de Beaumont O; Le Gall M;
J Allergy Clin Immunol; 2009 Jan; 123(1):160-166.e3. PubMed ID: 19046761
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
Malling HJ; Montagut A; Melac M; Patriarca G; Panzner P; Seberova E; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]